---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-151893"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2026-04-13T23:59:59+00:00"
generated_at: "2026-05-15T06:35:43.580826+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# IDEAYA announces Phase 2/3 trial met primary endpoint; darovasertib combo reduces progression risk by 58%

## Summary
- Darovasertib + crizotinib reduced risk of disease progression by 58% (HR 0.42, p<0.0001) in 1L HLA-A*02:01-negative mUM.
- Median PFS 6.9 months vs 3.1 months for investigator choice therapy (ICT) arm.
- ORR 37.1% vs 5.8% for ICT; 5 complete responses in combo arm, none in ICT.
- NDA submission to FDA targeted for second half of 2026.
- Safety profile manageable; Grade 3+ events included diarrhea, syncope, hypotension.

## SEC filing metadata
- accession: 0001193125-26-151893
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2026-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000119312526151893/0001193125-26-151893-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000119312526151893/d114952d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-151893
- JSON: https://secwatch.observer/filing/0001193125-26-151893.json
- Plain text: https://secwatch.observer/filing/0001193125-26-151893.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.